The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Dysregulation of the mevalonate pathway promotes transformation
Open accessAbstract
The importance of cancer metabolism has been appreciated for many years, but the intricacies of how metabolic pathways interconnect with oncogenic signaling are not fully understood. With a clear understanding of how metabolism contributes to tumorigenesis, we will be better able to integrate the targeting of these fundamental biochemical pathways into patient care. The mevalonate (MVA) pathway, paced by its rate-limiting enzyme, hydroxymethylglutaryl coenzyme A reductase (HMGCR), is required for the generation of several fundamental end-products including cholesterol and isoprenoids. Despite years of extensive research from the perspective of cardiovascular disease, the contribution of a dysregulated MVA pathway to human cancer remains largely unexplored. We address this issue directly by showing that dysregulation of the MVA pathway, achieved by ectopic expression of either full-length HMGCR or its novel splice variant, promotes transformation. Ectopic HMGCR accentuates growth of transformed and nontransformed cells under anchorage-independent conditions or as xenografts in immunocompromised mice and, importantly, cooperates with RAS to drive the transformation of primary mouse embryonic fibroblasts cells. We further explore whether the MVA pathway may play a role in the etiology of human cancers and show that high mRNA levels of HMGCR and additional MVA pathway genes correlate with poor prognosis in a meta-analysis of six microarray datasets of primary breast cancer. Taken together, our results suggest that HMGCR is a candidate metabolic oncogene and provide a molecular rationale for further exploring the statin family of HMGCR inhibitors as anticancer agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Regulation of the mevalonate pathway
Goldstein, J. L., & Brown, M. S. (1990) · Nature · doi:10.1038/343425a0 · Cited by 5,394
The Biology of Cancer: Metabolic Reprogramming Fuels Cell Growth and Proliferation
DeBerardinis, R. J., Lum, J. J., Hatzivassiliou, G., & Thompson, C. B. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2007.10.002 · Cited by 4,088
Tumor cell metabolism: cancer's Achilles' heel
Kroemer, G., & Pouyssegur, J. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.05.005 · Cited by 2,337
Sotiriou, C., Wirapati, P., Loi, S., Harris, A., Fox, S., Smeds, J., Nordgren, H., Farmer, P., Praz, V., Haibe-Kains, B., et al. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj052 · Cited by 2,063
Oncogenic pathway signatures in human cancers as a guide to targeted therapies
Bild, A. H., Yao, G., Chang, J. T., Wang, Q., Potti, A., Chasse, D., Joshi, M.-B., Harpole, D., Lancaster, J. M., Berchuck, A., et al. (2006) · Nature · doi:10.1038/nature04296 · Cited by 2,032
Genome-Wide Survey of Human Alternative Pre-mRNA Splicing with Exon Junction Microarrays
Johnson, J. M., Castle, J., Garrett-Engele, P., Kan, Z., Loerch, P. M., Armour, C. D., Santos, R., Schadt, E. E., Stoughton, R., & Shoemaker, D. D. (2003) · Science · doi:10.1126/science.1090100 · Cited by 1,418
Miller, L. D., Smeds, J., George, J., Vega, V. B., Vergara, L., Ploner, A., Pawitan, Y., Hall, P., Klaar, S., Liu, E. T., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506230102 · Cited by 1,268
Desmedt, C., Piette, F., Loi, S., Wang, Y., Lallemand, F., Haibe-Kains, B., Viale, G., Delorenzi, M., Zhang, Y., d'Assignies, M. S., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2765 · Cited by 968
The discovery and development of HMG-CoA reductase inhibitors.
Endo, A. (1992) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)41379-3 · Cited by 847
Pawitan, Y., Bjöhle, J., Amler, L., Borg, A.-L., Egyhazi, S., Hall, P., Han, X., Holmberg, L., Huang, F., Klaar, S., et al. (2005) · Breast Cancer Research · doi:10.1186/bcr1325 · Cited by 831
DeBose-Boyd, R. A. (2008) · Cell Research · doi:10.1038/cr.2008.61 · Cited by 391
Loi, S., Haibe-Kains, B., Desmedt, C., Wirapati, P., Lallemand, F., Tutt, A. M., Gillet, C., Ellis, P., Ryder, K., Reid, J. F., et al. (2008) · BMC Genomics · doi:10.1186/1471-2164-9-239 · Cited by 389
Rethinking the Warburg Effect with Myc Micromanaging Glutamine Metabolism
Dang, C. V. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3556 · Cited by 379
Hirsch, H. A., Iliopoulos, D., Joshi, A., Zhang, Y., Jaeger, S. A., Bulyk, M., Tsichlis, P. N., Shirley Liu, X., & Struhl, K. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.022 · Cited by 359
Mo, H., & Elson, C. E. (2004) · Experimental Biology and Medicine · doi:10.1177/153537020422900701 · Cited by 340
Dimitroulakos, J., Nohynek, D., Backway, K. L., Hedley, D. W., Yeger, H., Freedman, M. H., Minden, M. D., & Penn, L. Z. (1999) · Blood · doi:10.1182/blood.v93.4.1308 · Cited by 219
Self-citationStatin Use and Breast Cancer: Prospective Results From the Women's Health Initiative
Cauley, J. A., McTiernan, A., Rodabough, R. J., LaCroix, A., Bauer, D. C., Margolis, K. L., Paskett, E. D., Vitolins, M. Z., Furberg, C. D., & Chlebowski, R. T. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj188 · Cited by 179
Kwan, M. L., Habel, L. A., Flick, E. D., Quesenberry, C. P., & Caan, B. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9683-8 · Cited by 175 · cited 1×
“For example, use of lipophilic statins was associated with lower breast cancer incidence in a large group of over 150,000 postmenopausal women (15), and the risk of breast cancer recurrence decreased with increasing durations of postdiagnosis statin use (18).”
The oncogene c-Myc coordinates regulation of metabolic networks to enable rapid cell cycle entry
Morrish, F. M., Neretti, N., Sedivy, J. M., & Hockenbery, D. M. (2008) · Cell Cycle · doi:10.4161/cc.7.8.5739 · Cited by 158
Burkhardt, R., Kenny, E. E., Lowe, J. K., Birkeland, A. C., Josowitz, R., Noel, M., Salit, J., Maller, J., Pe’er, I., Daly, M. J., et al. (2008) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.172288 · Cited by 152
Karp, I., Behlouli, H., LeLorier, J., & Pilote, L. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2007.12.011 · Cited by 151
Metabolic Targeting as an Anticancer Strategy: Dawn of a New Era?
Pan, J. G., & Mak, T. W. (2007) · Science s STKE · doi:10.1126/stke.3812007pe14 · Cited by 147
Do the cholesterol-lowering properties of statins affect cancer risk?
Solomon, K. R., & Freeman, M. R. (2008) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2007.12.004 · Cited by 125
Medina, M. W., Gao, F., Ruan, W., Rotter, J. I., & Krauss, R. M. (2008) · Circulation · doi:10.1161/circulationaha.108.773267 · Cited by 119
Duncan, R. E., El-Sohemy, A., & Archer, M. C. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m400732200 · Cited by 113
Safety Profiles for the HMG-CoA Reductase Inhibitors
Davidson, M. H. (2001) · Drugs · doi:10.2165/00003495-200161020-00005 · Cited by 111
Exploiting the mevalonate pathway to distinguish statin-sensitive multiple myeloma
Clendening, J. W., Pandyra, A. A., Li, Z., Boutros, P. C., Martirosyan, A., Lehner, R. S., Jurišica, I., Trudel, S., & Penn, L. Z. (2010) · Blood · doi:10.1182/blood-2009-07-230508 · Cited by 102
Self-citationEstrogen Receptor–Negative Breast Cancer Is Less Likely to Arise among Lipophilic Statin Users
Kumar, A. S., Benz, C. C., Shim, V., Minami, C. A., Moore, D. H., & Esserman, L. J. (2008) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-07-0726 · Cited by 102
Menéndez, J. A., Decker, J. P., & Lupu, R. (2004) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20310 · Cited by 84
Determinants of sensitivity to lovastatin-induced apoptosis in multiple myeloma
Wong, W. W.-L., Clendening, J. W., Martirosyan, A., Boutros, P. C., Bros, C., Khosravi, F., Jurišica, I., Stewart, A. K., Bergsagel, P. L., & Penn, L. Z. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0745 · Cited by 79
Self-citationNewman, A., Clutterbuck, R. D., Powles, R., Catovsky, D., & Millar, J. L. (1997) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199709055590 · Cited by 77
HMG-CoA reductase inhibitors: role in normal and malignant cells
Larsson, O. (1996) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(96)00193-x · Cited by 74
Lipkin, S. M., Chao, E., Moreno, V. R., Rozek, L. S., Rennert, H. S., Pinchev, M., Dizon, D., Rennert, G., Kopelovich, L., & Gruber, S. B. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0007 · Cited by 74
The Role of HMGCR Alternative Splicing in Statin Efficacy
Medina, M. W., & Krauss, R. M. (2009) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2009.10.003 · Cited by 69
Borgquist, S., Djerbi, S., Pontén, F., Anagnostaki, L., Goldman, M., Gaber, A., Manjer, J., Landberg, G., & Jirström, K. (2008) · International Journal of Cancer · doi:10.1002/ijc.23597 · Cited by 66
Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer
Borgquist, S., Jögi, A., Pontén, F., Rydén, L., Brennan, D. J., & Jirström, K. (2008) · Breast Cancer Research · doi:10.1186/bcr2146 · Cited by 63
Regulation of HMG‐CoA reductase expression by hypoxia
Pallottini, V., Guantario, B., Martini, C., Totta, P., Filippi, I., Carraro, F., & Trentalance, A. (2008) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21757 · Cited by 53
Molowa, D. T., & Cimis, G. (1989) · Biochemical Journal · doi:10.1042/bj2600731 · Cited by 49
Brennan, D. J., Brändstedt, J., Rexhepaj, E., Foley, M., Pontén, F., Uhlén, M., Gallagher, W. M., O’Connor, D. P., O’Herlihy, C., & Jirström, K. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-125 · Cited by 49
Statins to reduce breast cancer risk: A case control study in U.S. female veterans
Kochhar, R., Khurana, V., Bejjanki, H. R., Caldito, G. C., & Fort, C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.514 · Cited by 41
Lee, P. C.-W., Nguyen, A. D., & DeBose‐Boyd, R. A. (2006) · Journal of Lipid Research · doi:10.1194/jlr.m600476-jlr200 · Cited by 19
Clerc, T., Sbarra, V., Domingo, N., Rault, J. P., Diaconescu, N., Moutardier, V., Hasselot, N., Lafont, H., Jadot, G., Laruelle, C., et al. (1996) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1996.tb15615.x · Cited by 10
Cited by
Santos, C. R., & Schulze, A. (2012) · The FEBS Journal · doi:10.1111/j.1742-4658.2012.08644.x · Cited by 1,335
How cancer metabolism is tuned for proliferation and vulnerable to disruption
Schulze, A., & Harris, A. L. (2012) · Nature · doi:10.1038/nature11706 · Cited by 929
Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway
Freed-Pastor, W. A., Mizuno, H., Zhao, X., Langerød, A., Moon, S.-H., Rodriguez-Barrueco, R., Barsotti, A., Chicas, A., Li, W., Polotskaia, A., et al. (2012) · Cell · doi:10.1016/j.cell.2011.12.017 · Cited by 865
Metabolic control of YAP and TAZ by the mevalonate pathway
Sorrentino, G., Ruggeri, N., Specchia, V., Cordenonsi, M., Mano, M., Dupont, S., Manfrin, A., Ingallina, E., Sommaggio, R., Piazza, S., et al. (2014) · Nature Cell Biology · doi:10.1038/ncb2936 · Cited by 776
Hooked on fat: the role of lipid synthesis in cancer metabolism and tumour development
Baenke, F., Peck, B., Miess, H., & Schulze, A. (2013) · Disease Models & Mechanisms · doi:10.1242/dmm.011338 · Cited by 772
Metadata
- Authors
- Clendening, J. W., Pandyra, A., Boutros, P. C., Ghamrasni, S. E., Khosravi, F., Trentin, G. A., Martirosyan, A., Hakem, A., Hakem, R., Jurisica, I., & Penn, L. Z.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2010-08-09
- Volume
- 107
- Issue
- 34
- Pages
- 15051-15056
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1970005961
- Cited by
- 417
- References
- 43
- FWCI
- 4.25
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.